All posts from Zacks
Zacks in Our Research. Your Success.,

BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss

BioScrip, Inc. BIOS reported net loss from continuing operations of 11 cents per share in the second quarter of 2017, compared to net loss of 8 cents a year ago. The Zacks Consensus Estimate was pegged at a loss of 10 cents. 


With the completion of the company’s non-core PBM business divestment (treated as discontinued operation in the previous quarter), BioScrip currently has a simplified business structure focused on core Infusion Services.

Revenues from continuing operations in the second quarter fell 6.2% year over year to $218.1 million and also missed the Zacks Consensus Estimate of $220 million. The year-over-year decline was due to the company’s shift in strategy to focus on growing its core revenue mix coupled with the impact of the Cures Act along with and contract modifications with UnitedHealthcare. This was partially offset by synergies from the Home Solutions acquisition.

BioScrip, Inc. Price, Consensus and EPS Surprise

Gross profit in the second quarter was .3 million, up 6.5% year over year. Gross margin also expanded 370 basis points (bps) to 31.3%. Adjusted operating income was $58.3 million, marking a 6.5% year-over-year increase despite a 6.5% rise in adjusted operating expenses to $10 million. Adjusted operating margin expanded 310 bps year over year to 26.7%.


BioScrip exited second-quarter 2017 with cash and cash equivalents of $40.5 million, significantly above $15.9 million recorded at the end of the first quarter.

2017 Guidance Intact

BioScrip reiterated its guidance for adjusted EBITDA at the range of $45.0–$55.0 million for full-year 2017. This guidance incorporates the estimated adverse effect of the Cures Act legislation and the company's estimates regarding its contract with UnitedHealthcare. The company has updated its revenue outlook for 2017 to a range of $815.0–$835.0 million including the impact of the revised UnitedHealthcare contract on its 2017 revenues. The Zacks Consensus Estimate for revenues of $855.2 million lies above the company’s guided range.

Our Take

BioScrip exited the second quarter on a dismal note with wider-than-expected loss and revenues missing the Zacks Consensus Estimate.Management’s 2017 guidance, which includes the negative impact of the Cures Act legislation, also adds to our concerns.

Nonetheless, we are encouraged by the company’s progress in the second quarter, courtesy of its new multi-faceted CORE plan which was adopted to improve the financial position. Further, the company achieved annualized supply chain improvement of roughly $20 million since the acquisition of Home Solutions’. The company expects core revenues at Home Solutions and continued core growth to prove accretive. Also, we are upbeat about the company raising the number of immunoglobulin or Ig therapy stocks by 15% from the previous quarter.

Zacks Rank & Other Key Picks

BioScrip has a Zacks Rank #2 (Buy). A few other top-ranked medical stocks are Edwards Lifesciences Corporation EW, INSYS Therapeutics, Inc. INSY and Align Technology, Inc. ALGN. Notably, Edwards Lifesciences, INSYS Therapeutics and Align Technology sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock posted a stellar four-quarter average earnings surprise of 60.7%.

Align Technology has an expected long-term adjusted earnings growth of almost 26.6%. The stock has added roughly 26.7% over the last three months.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 5% over the last three months.

More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future. 

Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
BioScrip, Inc. (BIOS): Free Stock Analysis Report
To read this article on click here.